Pharmacokinetics, Safety, and Tolerability of NNC0487-0111 in Obesity and Type 2 Diabetes Patients with Varying Renal Function

The primary objective of this study is to evaluate the **pharmacokinetics**, safety, and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with varying degrees of **renal impairment** and those with normal renal function. This is clinically relevant as it aims to understand how renal function affects the drug's behavior in the body, which is crucial for optimizing dosing regimens and ensuring patient safety, particularly in individuals with **obesity** and **Type 2 diabetes mellitus**. No secondary objectives are provided for this study.

The clinical trial involves participants diagnosed with **obesity** and **Type 2 diabetes mellitus**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. The trial population was selected to include individuals from both clinical trial groups 1 and 2, indicating a diverse representation of the affected demographic. Participants are considered part of a vulnerable population, which necessitates careful ethical considerations. However, the sponsor has not provided information regarding the total number of participants or specific lifestyle considerations such as diet, physical activity, or habits. Additionally, key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the **pharmacokinetics**, safety, and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with varying degrees of renal impairment and those with normal renal function. This study is a Phase 3, randomized, double-blind, controlled trial, which is expected to commence recruitment on August 1, 2024, and conclude by September 30, 2025. The trial will focus on individuals diagnosed with **obesity** and **Type 2 diabetes mellitus**. Participants will be involved in the study for a duration that aligns with the trial's timeline, with specific involvement periods determined by individual response and adherence to protocol.

The sequence of study visits includes an initial inclusion (screening) visit, where eligibility is assessed based on predefined criteria. Following successful screening, participants will undergo a baseline visit to establish initial health parameters. Subsequent follow-up visits will be scheduled to monitor the participants' response to the investigational product, assess safety, and collect pharmacokinetic data. The end-of-study visit will serve to evaluate the overall outcomes and ensure participant safety post-trial. The expected length of participant involvement will vary, but it is anticipated to align with the trial's estimated end date. Conditions that may lead to early termination from the study include adverse events, non-compliance with study procedures, or withdrawal of consent by the participant.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In addition to the experimental medication, the trial may include the use of **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatments. However, the data does not provide explicit details about these treatments. Information regarding the administration, dosing schedules, and participant compliance monitoring for these non-experimental treatments is also not available.

Due to the lack of specific information in the provided data, further details about the **experimental medication** and any **non-experimental treatments** used in the study cannot be elaborated upon. The trial documentation should be consulted for comprehensive information regarding the treatments involved in this clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on August 1, 2024, with an estimated completion date of September 30, 2025. The efficacy assessment will be conducted through a series of predefined parameters, although specific endpoints are not detailed in the available data. The trial will follow a structured methodology to ensure the accurate collection and analysis of efficacy data, adhering to the standards expected in a Phase 3 clinical trial. The trial's design will likely incorporate validated scales, laboratory tests, or patient-reported outcomes to measure efficacy, although these specific tools are not mentioned in the provided information. The trial will proceed according to a timeline that aligns with the typical progression of a Phase 3 study, ensuring that data collection is systematic and comprehensive.